The Food and Drug Administration has allowed Valencia drug maker MannKind Corp. to begin human testing on a cancer treatment it is developing. Enrollment in clinical trials on the experimental cancer drug MKC1106-PP will begin before the end of the year, the company said. The test will examine the effects on patients with solid tumors.